Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly neutralizing HIV antibodies that occur naturally have been characterized. To determine whether these antibodies are part of a larger group of related molecules, we cloned 576 new HIV antibodies from four unrelated individuals. All four individuals produced expanded clones of potent broadly neutralizing CD4-binding-site antibodies that mimic binding to CD4. Despite extensive hypermutation, the new antibodies shared a consensus sequence of 68 immunoglobulin H (IgH) chain amino acids and arise independently from two related IgH genes. Comparison of the crysta...
Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to tre...
HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as templates f...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...
Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests that v...
Antibodies against the CD4 binding site (CD4bs) on the HIV-1 spike protein gp120 can show exceptiona...
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reacti...
A large number of anti–HIV-1 antibodies targeting the CD4-binding site (CD4bs) on the envelope glyco...
SummaryThe site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly...
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reacti...
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reacti...
Current HIV-1 vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutr...
Current HIV-1 vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutr...
Antibodies against the CD4 binding site (CD4bs) on the HIV-1 spike protein gp120 can show exceptiona...
Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodi...
A large number of anti–HIV-1 antibodies targeting the CD4-binding site (CD4bs) on the envelope glyco...
Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to tre...
HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as templates f...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...
Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests that v...
Antibodies against the CD4 binding site (CD4bs) on the HIV-1 spike protein gp120 can show exceptiona...
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reacti...
A large number of anti–HIV-1 antibodies targeting the CD4-binding site (CD4bs) on the envelope glyco...
SummaryThe site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly...
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reacti...
The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reacti...
Current HIV-1 vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutr...
Current HIV-1 vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutr...
Antibodies against the CD4 binding site (CD4bs) on the HIV-1 spike protein gp120 can show exceptiona...
Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodi...
A large number of anti–HIV-1 antibodies targeting the CD4-binding site (CD4bs) on the envelope glyco...
Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to tre...
HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as templates f...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...